S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
66,000% upside on tiny biotech? (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
66,000% upside on tiny biotech? (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
California governor rejects bill to give unemployment checks to striking workers
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
66,000% upside on tiny biotech? (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
66,000% upside on tiny biotech? (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
California governor rejects bill to give unemployment checks to striking workers
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
66,000% upside on tiny biotech? (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
66,000% upside on tiny biotech? (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
California governor rejects bill to give unemployment checks to striking workers
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
66,000% upside on tiny biotech? (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
66,000% upside on tiny biotech? (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
California governor rejects bill to give unemployment checks to striking workers

Insulet (PODD) Stock Forecast, Price & News

$159.49
-4.37 (-2.67%)
(As of 09/29/2023 ET)
Compare
Today's Range
$158.84
$164.15
50-Day Range
$154.67
$281.74
52-Week Range
$152.43
$335.91
Volume
938,955 shs
Average Volume
1.24 million shs
Market Capitalization
$11.14 billion
P/E Ratio
179.20
Dividend Yield
N/A
Price Target
$280.40

Insulet MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
75.8% Upside
$280.40 Price Target
Short Interest
Healthy
4.12% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.20
Upright™ Environmental Score
News Sentiment
0.58mentions of Insulet in the last 14 days
Based on 14 Articles This Week
Insider Trading
Acquiring Shares
$1.01 M Bought Last Quarter
Proj. Earnings Growth
31.71%
From $1.64 to $2.16 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.07 out of 5 stars

Medical Sector

24th out of 972 stocks

Surgical & Medical Instruments Industry

4th out of 99 stocks


PODD stock logo

About Insulet (NASDAQ:PODD) Stock

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

PODD Price History

PODD Stock News Headlines

14 Analysts Have This to Say About Insulet
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Insulet Stock Begins to Show Signs of Life
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Insulet Corp PODD Stock Quote
Insulet (PODD) Expands Omnipod 5 Even As Macro Woes Linger
Why Insulet Stock Is Sinking Today
What 12 Analyst Ratings Have To Say About Insulet
James Hollingshead Bought 76% More Shares In Insulet
Why Insulet Stock Rocked the Market Today
President and CEO of Insulet Makes $1.01M Buy
See More Headlines
Receive PODD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter.

PODD Company Calendar

Last Earnings
8/08/2023
Today
10/01/2023
Next Earnings (Confirmed)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:PODD
CUSIP
45784P10
Employees
2,600
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$280.40
High Stock Price Forecast
$350.00
Low Stock Price Forecast
$185.00
Forecasted Upside/Downside
+75.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
16 Analysts

Profitability

Net Income
$4.60 million
Pretax Margin
4.76%

Debt

Sales & Book Value

Annual Sales
$1.31 billion
Cash Flow
$2.22 per share
Book Value
$6.86 per share

Miscellaneous

Free Float
69,193,000
Market Cap
$11.14 billion
Optionable
Optionable
Beta
0.81

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. James R. Hollingshead Ph.D. (Age 60)
    Pres, CEO & Director
    Comp: $2.18M
  • Mr. Wayde D. McMillan (Age 52)
    Exec. VP,CFO & Treasurer
    Comp: $1.15M
  • Ms. Shacey PetrovicMs. Shacey Petrovic (Age 49)
    Director & Advisor
    Comp: $2.96M
  • Mr. Eric BenjaminMr. Eric Benjamin (Age 40)
    Exec. VP, Chief Product & Customer Experience Officer
    Comp: $947.57k
  • Mr. Prem Singh (Age 46)
    Sr. VP of Global Operations
  • Ms. Lauren Budden
    VP, Chief Accounting Officer & Controller
  • Mr. Mark Field
    Sr. VP & CTO
  • Ms. Deborah R. Gordon CPA (Age 53)
    VP of Investor Relations
  • Mr. John Wodick Kapples (Age 63)
    Sr. VP & Gen. Counsel
  • Ms. Laetitia Cousin (Age 47)
    Sr. VP of Regulatory Affairs, Quality Assurance & Compliance













PODD Stock - Frequently Asked Questions

Should I buy or sell Insulet stock right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last twelve months. There are currently 7 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PODD shares.
View PODD analyst ratings
or view top-rated stocks.

What is Insulet's stock price forecast for 2023?

16 brokerages have issued 1-year price objectives for Insulet's stock. Their PODD share price forecasts range from $185.00 to $350.00. On average, they expect the company's stock price to reach $280.40 in the next year. This suggests a possible upside of 75.8% from the stock's current price.
View analysts price targets for PODD
or view top-rated stocks among Wall Street analysts.

How have PODD shares performed in 2023?

Insulet's stock was trading at $294.39 at the beginning of 2023. Since then, PODD stock has decreased by 45.8% and is now trading at $159.49.
View the best growth stocks for 2023 here
.

Are investors shorting Insulet?

Insulet saw a drop in short interest in September. As of September 15th, there was short interest totaling 2,880,000 shares, a drop of 13.5% from the August 31st total of 3,330,000 shares. Based on an average daily trading volume, of 1,020,000 shares, the days-to-cover ratio is currently 2.8 days.
View Insulet's Short Interest
.

When is Insulet's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our PODD earnings forecast
.

How can I listen to Insulet's earnings call?

Insulet will be holding an earnings conference call on Thursday, November 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) announced its quarterly earnings results on Tuesday, August, 8th. The medical instruments supplier reported $0.38 earnings per share for the quarter, beating analysts' consensus estimates of $0.24 by $0.14. The medical instruments supplier earned $396.50 million during the quarter, compared to analysts' expectations of $383.97 million. Insulet had a net margin of 4.29% and a trailing twelve-month return on equity of 22.42%.

What guidance has Insulet issued on next quarter's earnings?

Insulet updated its third quarter 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $402.14 million-$412.37 million, compared to the consensus revenue estimate of $400.90 million.

What is Shacey Petrovic's approval rating as Insulet's CEO?

61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD).

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

How do I buy shares of Insulet?

Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $159.49.

How much money does Insulet make?

Insulet (NASDAQ:PODD) has a market capitalization of $11.14 billion and generates $1.31 billion in revenue each year. The medical instruments supplier earns $4.60 million in net income (profit) each year or $0.89 on an earnings per share basis.

How many employees does Insulet have?

The company employs 2,600 workers across the globe.

How can I contact Insulet?

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The official website for the company is www.insulet.com. The medical instruments supplier can be reached via phone at (978) 600-7000, via email at ir@insulet.com, or via fax at 978-600-0120.

This page (NASDAQ:PODD) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -